scholarly journals Complete Genome Sequences of Dengue Virus Type 1 to 4 Strains Used for the Development of CBER/FDA RNA Reference Reagents and WHO International Standard Candidates for Nucleic Acid Testing

2016 ◽  
Vol 4 (1) ◽  
Author(s):  
Germán Añez ◽  
Daniel A. Heisey ◽  
Evgeniya Volkova ◽  
Maria Rios

Dengue virus (DENV), a member of the Flaviviridae family, is the most common and clinically significant arbovirus in the world and is endemic in more than 100 countries. Here, we report the complete sequences of four DENV serotypes used in the development of the CBER/FDA RNA reference reagents and WHO International Standard candidates for nucleic acid testing.

2015 ◽  
Vol 781 ◽  
pp. 637-640
Author(s):  
Thitiwat Piyatamrong ◽  
Anan Kamolphanus ◽  
Gasydech Lergchinnaboot ◽  
Krittin Suphakarn ◽  
Chivalai Temiyasathit

Dengue virus (DENV) is one of the most widespread infectious diseases in the world, especially in the South East Asian regions. Transmitting the virus through mosquitoes, Dengue is an infectious viral borne disease. The virus sequences are assembled as series of nucleic acid, making the task of diagnosing virus sequences burdensome. Graphical representations are then proposed to represent Dengue virus to sustain the studies in virus sequences diagnosis. However, graphically representing sequences remained a crucified task especially for the incomplete genome sequences due to the missing nucleic acids. Although a number of studies provide methodologies on virus sequence visualization, in Dengue virus researches, those methodologies provide the visualization solely for complete genome sequences while neglecting the incomplete genome sequences. With the unaccommodating availabilities of research inputs, our study proposes a methodology for graphically representing the incomplete Dengue virus sequences, as well as complete virus sequences, by imputing in the incomplete part of a sequence with created reference sequences. The proposed methodology employs the use of database technology and majority voting technique to create reference sequences for each serotype of Dengue. Experimental results show that incomplete sequences are visualized realistically according to its respective serotype, thus providing flexibilities in Dengue virus researches to compensate incomplete sequences as inputs.


2017 ◽  
Vol 55 (3) ◽  
pp. 923-930 ◽  
Author(s):  
Susanna K. Tan ◽  
Stephen Milligan ◽  
Malaya K. Sahoo ◽  
Nathaniel Taylor ◽  
Benjamin A. Pinsky

ABSTRACT Significant interassay variability in the quantification of BK virus (BKV) DNA precludes establishing broadly applicable thresholds for the management of BKV infection in transplantation. The 1st WHO International Standard for BKV (primary standard) was introduced in 2016 as a common calibrator for improving the harmonization of BKV nucleic acid amplification testing (NAAT) and enabling comparisons of biological measurements worldwide. Here, we evaluated the Altona RealStar BKV assay (Altona) and calibrated the results to the international unit (IU) using the Exact Diagnostics BKV verification panel, a secondary standard traceable to the primary standard. The primary and secondary standards on Altona had nearly identical linear regression equations (primary standard, Y = 1.05X − 0.28, R 2 = 0.99; secondary standard, Y = 1.04X − 0.26, R 2 = 0.99) and conversion factors (primary standard, 1.11 IU/copy; secondary standard, 1.09 IU/copy). A comparison of Altona with a laboratory-developed BKV NAAT assay in IU/ml versus copies/ml using Passing-Bablok regression revealed similar regression lines, no proportional bias, and improvement in the systematic bias (95% confidence interval of intercepts: copies/ml, −0.52 to −1.01; IU/ml, 0.07 to −0.36). Additionally, Bland-Altman analyses revealed a clinically significant reduction of bias when results were reported in IU/ml (IU/ml, −0.10 log 10 ; copies/ml, −0.70 log 10 ). These results indicate that the use of a common calibrator improved the agreement between the two assays. As clinical laboratories worldwide use calibrators traceable to the primary standard to harmonize BKV NAAT results, we anticipate improved interassay comparisons with a potential for establishing broadly applicable quantitative BKV DNA load cutoffs for clinical practice.


Transfusion ◽  
2017 ◽  
Vol 57 (3pt2) ◽  
pp. 748-761 ◽  
Author(s):  
Sally A. Baylis ◽  
Kay-Martin O. Hanschmann ◽  
Barbara S. Schnierle ◽  
Jan-Hendrik Trösemeier ◽  
Johannes Blümel ◽  
...  

Transfusion ◽  
2013 ◽  
Vol 53 (10pt2) ◽  
pp. 2422-2430 ◽  
Author(s):  
Benjamin Müller ◽  
C. Micha Nübling ◽  
Julia Kress ◽  
W. Kurt Roth ◽  
Silke De Zolt ◽  
...  

Virus Genes ◽  
2009 ◽  
Vol 40 (1) ◽  
pp. 60-66 ◽  
Author(s):  
S. E. S. Carvalho ◽  
D. P. Martin ◽  
L. M. Oliveira ◽  
B. M. Ribeiro ◽  
T. Nagata

2021 ◽  
Author(s):  
Xiaolong Su ◽  
Man Zhou

Abstract Background Currently, coronavirus disease 2019 (COVID-19) has become the most severe infectious disease affecting the world, which has spread around the world to more than 200 countries in 2020. Until COVID-19 vaccine technology completely matures, nucleic acid testing is considered as an effective way to screen virus carriers and control the spread of the virus. Considering that the medical resources and infection rates are different across various countries and regions, if all infected areas adopt the traditional individual nucleic acid testing method, the workload will be heavy and time-consuming. Therefore, this will not lead to the control of the pandemic. Methods After Wuhan completed a citywide nucleic acid testing in May 2020, China basically controlled the spread of COVID-19 and entered the post-epidemic period. Since then, although some cities in China, such as Qingdao, Xinjiang, Beijing, Dalian, have experienced a local epidemic resurgence, the pandemic was quickly suppressed through wide-scale pooled nucleic acid testing methods. Combined with the successful experience of mass nucleic acid testing in China, this study introduces two main pooled testing methods used in two cities with a population of more than ten million people, Wuhan’s “five-in-one” and Qingdao's “ten-in-one” rapid pooled testing methods. This study proposes an improved method for optimising the second round of “ten-in-one” pooled testing, known as “the pentagram mini-pooled testing method”, which speeds up the testing process (as a result of reducing the numbers of testing by 40%) and significantly reduces the cost. Findings Qingdao's optimised “ten-in-one” pooled testing method quickly screens out the infections by running fewer testing. This study also mathematically examines the probabilistic principles and applicability conditions for pooled testing of COVID-19. Herein, the study theoretically determines the optimal number of samples that could successfully be combined into a pool under different infection rates. Then, it quantitatively discusses the applicability and principles for choosing the pooled testing instead of individual testing.Interpretation Overall, this research offers a reference for other countries with different infection rates to help them in implementing the mass testing for COVID-19 to reduce the spread of coronavirus.


2016 ◽  
Vol 4 (5) ◽  
Author(s):  
Jan-Hendrik Trösemeier ◽  
Didier Musso ◽  
Johannes Blümel ◽  
Julien Thézé ◽  
Oliver G. Pybus ◽  
...  

We report here the sequence of a candidate reference strain of Zika virus (ZIKV) developed on behalf of the World Health Organization (WHO). The ZIKV reference strain is intended for use in nucleic acid amplification (NAT)-based assays for the detection and quantification of ZIKV RNA.


Sign in / Sign up

Export Citation Format

Share Document